We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
With support from the founders of Bulldog Skincare, Zoopla and Love Film, VITL's aim is to improve the nation's health by offering vitamin packs that are fully personalised to the customer. VITL uses artificial intelligence to decipher which nutrients a person needs to ensure a healthy lifestyle. Effectively cutting out the cost of a private nutritionist.

Pitch Rated

44%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £908,950
WeTRAIN is a new way to have fun with personal training. They are the first shared personal training company and by doing this, they are creating a market of social exercise. WeTRAIN makes it easy for friends to have high quality, personalised training in a variety of different classes.
days to go: Expired investment: £437,138
Capital Physio is one of the UK’s fastest growing providers of retail physiotherapy. Since inception in 2012, the group has opened 17 clinics as part of a highly scalable and growth driven business model.  
days to go: Expired investment: £6,210
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £142,026
Six to Start are the co-creators of the popular fitness game 'Zombies, run!' and are now raising investment to grow this and to also build a new app called 'Virtual Races.' With over 3,000,000 downloads and peaks of 250k monthly active users, Zombie, Run! brings together audio storytelling and gameplay with real-world exercise. Virtual Races has already attracted over 15,000 entrants and generated over £600K+ in revenue.   
days to go: Expired investment: £249,970
Amchara Health specialises in bringing a better approach to creating a personalised health solution tailored to a person's needs and goals. Its aim is to educate and empower people about better health choices. This residential retreat brand is developing three health & wellness applications: HealthHub360, MyAmchara, and Amchara360. In the first 12 months, the company will aim to achieve more than 100,000 downloads of the Healthhub360 application. With the proceeds, Amchara will be marketing the MyAmchara app and rebrand it. Furthermore, there will be an international development of the application to cater to Canada, Australia, and the USA.
days to go: Expired investment: £167,619
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph